KIM, YUNTAE,金润泰,金潤泰,LEE, CHANG SIK,李昌埴,OH, JUNG TAEK,吴正泽,吳正澤,SONG, HYESEUNG,宋彗丞,CHOI, JIN,崔眞,LEE, JAEYOUNG,李在英
申请号：
TW105132939
公开号：
TW201716397A
申请日:
2016.10.12
申请国别(地区):
TW
年份:
2017
代理人:
摘要：
The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases； neoplasms； endocrine, nutritional and metabolic diseases； mental and behavioral disorders； neurological diseases； diseases of the eye and adnexa； cardiovascular diseases； respiratory diseases； digestive diseases； diseases of the skin and subcutaneous tissue； diseases of the musculoskeletal system and connective tissue； or congenital malformations, deformations and chromosomal abnormalities.本發明係關於具有組蛋白去乙醯酶6 (HDAC6)抑制活性之新穎化合物、其立體異構物或其醫藥上可接受之鹽、其用於製備治療藥劑之用途、含有彼之醫藥組合物、使用該組合物治療疾病之方法及製備該等新穎化合物之方法。 本發明之該等新穎化合物、其立體異構物或其醫藥上可接受之鹽具有組蛋白去乙醯酶(HDAC)抑制活性且可有效用於預防或治療HDAC6介導之疾病，包括傳染病；贅瘤；內分泌、營養及代謝疾病；精神及行為障礙；神經疾病；眼部及附件疾病；心血管疾病；呼吸疾病；消化性疾病；皮膚及皮下組織疾病；肌肉骨骼系統及結締組織疾病；或先天性畸形、變形及染色體異常。
